<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="92495">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02006654</url>
  </required_header>
  <id_info>
    <org_study_id>14863A</org_study_id>
    <secondary_id>2012-004765-40</secondary_id>
    <nct_id>NCT02006654</nct_id>
  </id_info>
  <brief_title>Lu AE58054 in Patients With Mild to Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor</brief_title>
  <acronym>STARBRIGHT</acronym>
  <official_title>Randomised, Double-blind, Parallel-group, Placebo-controlled Study of Lu AE58054 in Patients With Mild to Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish efficacy of Lu AE58054 as adjunctive therapy to acetylcholinesterase inhibitors
      (AChEIs) for symptomatic treatment of patients with mild-moderate Alzheimer's disease (AD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in cognition</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) total score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in global impression</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in functioning</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL23) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in behavioural disturbance</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Neuropsychiatric Inventory (NPI) total score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in individual behavioural disturbance items</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in single NPI item scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anxiety</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in NPI Anxiety item score based on a pre-specified NPI Anxiety score at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical worsening</measure>
    <time_frame>Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Based on pre-specified ADAS-cog, ADCS-ADL23, and ADCS-CGIC changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cognitive aspects of mental function</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in Mini Mental State Examination (MMSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of life (EQ-5D)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in EuroQol 5-dimensional (EQ-5D) utility score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health-related quality of  (EQ-5D VAS)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in EQ-5D Visual Analogue Scale (EQ-5D VAS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (AEs)</measure>
    <time_frame>Up to 24 weeks and a 4-week safety follow up</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Overview of AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who withdrew due to intolerance to treatment</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of suicidality</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Columbia Suicide Severity Rating Scale (C-SSRS)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo adjunct to base treatment with an AChEI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lu AE58054 60 mg (or 30 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lu AE58054 adjunct to base treatment with an ACHEI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily, matching placebo capsules, orally</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AE58054</intervention_name>
    <description>Once daily, encapsulated tablets, orally</description>
    <arm_group_label>Lu AE58054 60 mg (or 30 mg)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a knowledgeable and reliable caregiver.

          -  The patient is an outpatient.

          -  The patient has probable AD.

          -  The patient has mild to moderate AD.

          -  Stable treatment with an AChEI.

          -  The patient, if a woman, must have had her last natural menstruation â‰¥24 months prior
             to baseline, OR be surgically sterile.

          -  The patient, if a man, agrees to protocol-defined use of effective contraception if
             his female partner is of childbearing potential, OR must have been surgically
             sterilised prior to the screening visit.

        Exclusion Criteria:

          -  The patient has evidence of any clinically significant neurodegenerative disease, or
             other serious neurological disorders other than AD.

          -  The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
             Text Revision (DSM-IV-TR) Axis I disorder other than AD.

          -  The patient has evidence of clinically significant disease.

          -  The patient's current AChEI therapy is likely to be interrupted or discontinued
             during the study.

          -  The patient is currently receiving memantine or has taken memantine within 2 months
             prior to screening.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <email>LundbeckClinicalTrials@lundbeck.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>US606</name>
      <address>
        <city>Prairie Village</city>
        <state>Kansas</state>
        <zip>66206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>December 5, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cholinesterase Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
